Novel Markers for Detecting Early Progression of Glaucoma
1 other identifier
observational
250
1 country
1
Brief Summary
Current methods of detecting glaucoma and monitoring its progression over time involve visual assessment of the optic nerve, thickness measurements of nerve tissue in the eye (using optical coherence tomography, OCT) as well as functional tests which measure peripheral, or side, vision. The objective of this study is to determine if a new technique of measuring blood flow in the eye, using OCT, can be used to better detect and/or monitor changes in glaucoma patients and suspects than these methods.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 5, 2017
CompletedFirst Posted
Study publicly available on registry
April 11, 2017
CompletedStudy Start
First participant enrolled
April 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedFebruary 17, 2025
February 1, 2025
8.1 years
April 5, 2017
February 14, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Blood flow
Establish whether blood flow changes occur and if there are differences in the groups.
Changes over the 5 year course of the study
Secondary Outcomes (1)
Optic nerve head (ONH) anatomy
Changes over the 5 year course of the study
Study Arms (2)
Glaucoma
Subjects identified as having glaucoma. No interventions will be performed.
Healthy controls
Subjects identified as having healthy eyes with no disease.
Interventions
All subjects will have OCT angiography imaging performed
Eligibility Criteria
Glaucoma patients recruited from a Primary Care Clinic Healthy control subjects recruited from the general population
You may qualify if:
- visual acuity ≥ 6/12
- glaucomatous ONH change
- glaucomatous visual field loss with a positive Glaucoma Hemifield Test
You may not qualify if:
- non-glaucomatous ocular disease
- chronic systemic disease or treatment affecting the visual field
- refraction exceeding 6 D equivalent sphere or 3 D astigmatism
- inability to provide informed consent
- Control Group
- visual acuity ≥ 6/12
- normal eye examination with intraocular pressure ≤ 21 mm Hg
- normal visual field and negative Glaucoma Hemifield Test
- chronic ocular disease
- chronic systemic disease or treatment affecting the visual field
- refraction exceeding 6 D equivalent sphere or 3 D astigmatism
- inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Eye Care Centre
Halifax, Nova Scotia, B3H 2Y9, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Balwantray Chauhan, PHD
Nova Scotia Health Authority
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Mathers Professor and Research Director
Study Record Dates
First Submitted
April 5, 2017
First Posted
April 11, 2017
Study Start
April 1, 2018
Primary Completion
May 1, 2026
Study Completion
May 1, 2026
Last Updated
February 17, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share